The four-pronged strategy begins with the acquisition of GSK's oncology portfolio, which includes all of its marketed products and late-stage candidates, for $14.5 billion, with a further $1.5 ...

The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal infection for use in people aged 10 through 25 years, the company said on ...

We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other best ...

Something seems to be going awry with GlaxoSmithKline's game plan for its respiratory franchise, with new products positioned to replace ageing blockbuster Advair/Seretide not performing in the field.

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...

GlaxoSmithKline sues Pfizer and BioNTech ... two deals with Pfizer worth a combined $897 million to manufacture products for the U.S. pharmaceutical giant. May 19, 2023 Abbott's India arm posts ...

This year, GSK expects to launch five new products/line extensions, including Blenrep (relaunch in multiple myeloma), depemokimab (for severe asthma and chronic rhinosinusitis with nasal polyps ...